159 related articles for article (PubMed ID: 21826053)
21. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Di L; Kerns EH; Li SQ; Carter GT
Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
[TBL] [Abstract][Full Text] [Related]
22. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
[TBL] [Abstract][Full Text] [Related]
23. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
Niwa T; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
[TBL] [Abstract][Full Text] [Related]
24. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
25. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
26. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.
Wu Z; Lee D; Joo J; Shin JH; Kang W; Oh S; Lee DY; Lee SJ; Yea SS; Lee HS; Lee T; Liu KH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5448-56. PubMed ID: 23959307
[TBL] [Abstract][Full Text] [Related]
27. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
28. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
29. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
30. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes.
Ji HY; Lee H; Lim SR; Kim JH; Lee HS
Molecules; 2012 Jan; 17(1):851-60. PubMed ID: 22252501
[TBL] [Abstract][Full Text] [Related]
31. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
Weiss J; Sawa E; Riedel KD; Haefeli WE; Mikus G
Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):275-82. PubMed ID: 18516595
[TBL] [Abstract][Full Text] [Related]
33. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
34. Potent inhibitory effect of alpha-viniferin on human cytochrome P450.
Sim J; Jang HW; Song M; Kim JH; Lee SH; Lee S
Food Chem Toxicol; 2014 Jul; 69():276-80. PubMed ID: 24769006
[TBL] [Abstract][Full Text] [Related]
35. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes.
Misaka S; Kawabe K; Onoue S; Werba JP; Giroli M; Tamaki S; Kan T; Kimura J; Watanabe H; Yamada S
Drug Metab Pharmacokinet; 2013; 28(3):244-9. PubMed ID: 23268924
[TBL] [Abstract][Full Text] [Related]
36. Comparison of metabolism of sesamin and episesamin by drug-metabolizing enzymes in human liver.
Yasuda K; Ikushiro S; Wakayama S; Itoh T; Yamamoto K; Kamakura M; Munetsuna E; Ohta M; Sakaki T
Drug Metab Dispos; 2012 Oct; 40(10):1917-26. PubMed ID: 22752007
[TBL] [Abstract][Full Text] [Related]
37. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
38. In vitro metabolism of corydaline in human liver microsomes and hepatocytes using liquid chromatography-ion trap mass spectrometry.
Ji HY; Lee H; Kim JH; Kim KH; Lee KR; Shim HJ; Son M; Lee HS
J Sep Sci; 2012 May; 35(9):1102-9. PubMed ID: 22689485
[TBL] [Abstract][Full Text] [Related]
39. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
40. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M; Svensson JO; Krausz KW; Gelboin HV; Rane A; Tybring G
Eur J Clin Pharmacol; 2004 May; 60(3):173-82. PubMed ID: 15054565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
